Trial · NCT07912190
ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis
NCT07912190, Recruiting, Qian Chu
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis. Trials, record NCT07912190. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912190
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ePRO in Advanced Lung Cancer: Emotional Distress, Symptom Burden, Brain Metastasis
- NCT number
- NCT07912190
- Status
- Recruiting
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Qian Chu
- Conditions
- Lung Cancer, Brain Metastasis, Patient Reported Outcome
- Interventions
- Patient reported outcome
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To clarify the number of symptom clusters, changes in emotional stress, the composition of symptoms within each cluster, and their dynamic temporal trends during treatment | Completed 1-2 days before treatment initiation; assessments were conducted every 4 weeks in the first six months after treatment, and every 8 weeks thereafter until disease progression. | MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC): The scale ranges from 0 to 10, with higher scores indicating greater symptom burden. |
| Secondary | questionnaire response rate | from baseline to the 12th month | The response rate of the MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) will be assessed every 4 weeks within the first six months of treatment and every 8 weeks thereafter until disease progression. This indicator reflects the proportion of patients who complete the MDASI-LC at each time point. A higher response rate indicates better participant engagement and superior data quality. |
| Secondary | The correlations of patients' emotional stress status and symptom severity scores with brain metastasis and PFS | from baseline to the 12th month | Patients completed the MDASI-LC, PHQ-9 and GAD-7 scales from baseline to month 12. Meanwhile, the correlations between relevant indicators and patients' PFS were analyzed. |
| Secondary | changes in quality of life over time | from baseline to the 12th month | Quality of life will be assessed using the EuroQol 5-Dimension Health Questionnaire (EQ-5D), a widely validated tool for measuring general health status. The EQ-5D covers five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Changes in scores will be evaluated from baseline to 12 weeks after the completion of chemotherapy. Higher EQ-5D scores indicate a better quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07912190
GET https://conductscience.org/api/trials/v1/NCT07912190/registered